A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.

A Phase I (First-in-human) Randomized, Double-blind, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects With Mild to Moderate Plaque Psoriasis.

This is a first-in-human, randomized, double- blind, placebo-controlled, dose escalation study to investigate how different doses of CAN10 are tolerated, taken up by the body and how long CAN10 stays in the body. In the first part of the study, the single ascending dose (SAD) cohorts, CAN10 will be given as a single intravenous dose to healthy subjects. In the second part of the study, the multiple ascending dose (MAD) cohorts, CAN10 will be given as repeated subcutaneous doses to participants with mild to moderate plaque psoriasis.

Study Overview

• Status: Completed
• Conditions: Healthy; Plaque Psoriasis
• Intervention / Treatment: Biological: CAN10; Biological: CAN10 - Placebo

• Study Type: Interventional
• Enrollment (Actual): 80
• Phase: Phase 1

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 13627
    • CRS Clinical Research Services Berlin GmbH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male or female, aged 18 to 50 years of age (inclusive) at the time of signing informed consent.
• Body mass index (BMI) 18 to 30 kg/m2 (inclusive) and a weight between 50 to 100 kg (inclusive) at the time of screening
• Considered by the investigator to be in good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening.
• Female subjects of childbearing potential must use a highly effective method of birth control and have a negative pregnancy test at screening and before the first dose of study drug. Male subjects with female partners must agree to use a condom, and their female partners are recommended to use a highly effective method of birth control.

Additionally for subjects with plaque psoriasis only:

• A diagnosis of plaque psoriasis with Psoriasis Area Severity Index (PASI) score ≥3 to ≤15 and Physician Global Assessment (PGA) score ≥2 (mild) to <4 (moderate).
• No disease manifestation requiring systemic immunosuppressive therapy.

Exclusion Criteria:

• History or presence of:

  1. Severe allergy/hypersensitivity (subjects with mild pollen allergy can be included).
  2. Significant kidney, liver, or urologic disease.
  3. Clinically significant psychiatric disorders
  4. Tuberculosis (TB) infection or positive QuantiFERON TB Gold test
  5. Any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
• Clinically significant illness, medical/surgical procedure, or trauma within 4 weeks before the first dose of study drug.
• Ongoing opportunistic or systemic infections
• A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antigen or antibodies at screening.

Additionally for subjects with plaque psoriasis only:

• Psoriasis other than a plaque variant.
• Any sign of infection of any of the psoriatic lesions.

• Use of any of the following treatments within the indicated washout period before the first dose of study drug:

  1. 12 weeks or 5 half-lives (whichever is longer) for biologic agents known or expected to impact the course of psoriasis or its assessments.
  2. 12 weeks for oral retinoids
  3. 8 weeks for cyclosporin, interferon, methotrexate, other systemic immunosuppressive or immunomodulating agents, or psoralen plus ultraviolet A (UVA)
  4. 2 weeks for immunizations or drugs known to possibly worsen psoriasis, unless on a stable dose for >12 weeks
  5. 1 week for topical treatments: corticosteroids, immunomodulators, anthralin (dithranol), Vitamin D derivatives, retinoids, or coal tar (used on the body)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CAN10 single ascending dose; A single dose of CAN10 will be administered intravenously (IV) to healthy subjects.	Biological: CAN10; Single dose intravenous or Multiple doses subcutaneously
Placebo Comparator: CAN10 single ascending dose - placebo; A single dose of matching placebo will be administered intravenously (IV) to healthy subjects.	Biological: CAN10 - Placebo; Single dose intravenous or Multiple doses subcutaneously
Experimental: CAN10 multiple ascending dose; Multiple doses of CAN10 will be administered subcutaneously (SC) to subjects with mild to moderate plaque psoriasis	Biological: CAN10; Single dose intravenous or Multiple doses subcutaneously
Placebo Comparator: CAN10 multiple ascending dose - placebo; Multiple doses of matching placebo will be administered subcutaneously (SC) to subjects with mild to moderate plaque psoriasis	Biological: CAN10 - Placebo; Single dose intravenous or Multiple doses subcutaneously

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To investigate the safety and tolerability of single and multiple ascending doses of CAN10	Frequency, seriousness, and intensity of treatment-emergent adverse events (TEAEs) in subjects receiving single and multiple doses of CAN10	From the day of the first dose until day 57 after the last dose

Secondary Outcome Measures

Outcome Measure	Time Frame
Assessment of Area under plasma concentration time curve (AUC) from time 0 extrapolated to infinity (AUCinf) after single (IV) dosing	From the day of dosing (day 1) until day 57 after dosing
Assessment of AUC from time zero to last measurable serum concentration (AUClast) following single (IV) and multiple (SC) dosing	From the day of the first dose until day 57 after the last dose
Assessment of AUC from time 0 to 336 hours post dose (i.e., AUC over a 2-week interval) after multiple (SC) dosing on Day 36 (AUC0-336,MD)	From the last dose until 336 hours after the last dose
Assessment of the maximum observed concentration (Cmax) following single (IV) and multiple (SC) dosing	From the day of the first dose until day 57 after the last dose
Assessment of time to maximum observed serum concentration (Tmax) following single (IV) and multiple (SC) dosing	From the day of the first dose until day 57 after the last dose
Assessment of the terminal elimination rate constant (λz) following single (IV) and multiple (SC) dosing	From the day of the first dose until day 57 after the last dose
Assessment of the terminal halflife (t1/2) following single (IV) and multiple (SC) dosing	From the day of the first dose until day 57 after the last dose
Assessment of the total clearance (CL) following single (IV) dosing)	From the day of dosing (day 1) until day 57 after dosing
Assessment of the volume of distribution (Vd) following single (IV) dosing	From the day of dosing (day 1) until day 57 after dosing
Assessment of total clearance following extravascular administration (CL/F) following multiple (SC) dosing	From the day of the first dose until day 57 after the last dose
Assessment of volume of distribution following extravascular administration (Vd/F) following multiple (SC) dosing	From the day of the first dose until day 57 after the last dose

Collaborators and Investigators

• Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Investigators: Principal Investigator: Manuela Casjens, MD, CRS Clinical Research Services Berlin GmbH

Publications and helpful links

General Publications

• Mulholland M, Depuydt MAC, Jakobsson G, Ljungcrantz I, Grentzmann A, To F, Bengtsson E, Jaensson Gyllenback E, Gronberg C, Rattik S, Liberg D, Schiopu A, Bjorkbacka H, Kuiper J, Bot I, Slutter B, Engelbertsen D. Interleukin-1 receptor accessory protein blockade limits the development of atherosclerosis and reduces plaque inflammation. Cardiovasc Res. 2024 May 7;120(6):581-595. doi: 10.1093/cvr/cvae046.

Study record dates

Study Major Dates

• Study Start (Actual): August 21, 2023
• Primary Completion (Actual): November 10, 2025
• Study Completion (Actual): November 10, 2025

Study Registration Dates

• First Submitted: November 16, 2023
• First Submitted That Met QC Criteria: November 16, 2023
• First Posted (Actual): November 22, 2023

Study Record Updates

• Last Update Posted (Actual): February 5, 2026
• Last Update Submitted That Met QC Criteria: February 3, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis
• Other Study ID Numbers: CAN10CLIN001; 2023-504450-35 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No